We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBE SCIENTIFIC, LLC

Download Mobile App




Plasma Markers Predict Brain Amyloid Burden in AD

By LabMedica International staff writers
Posted on 23 Feb 2018
Aggregation and accumulation of beta-amyloid (Aβ), particularly Aβ42, is implicated in the pathogenesis of Alzheimer's disease (AD) with overproduction in autosomal-dominant AD and impaired clearance in the presence of amyloidosis contributing to the cause of AD.

Cerebrospinal fluid analysis and other measurements of amyloidosis, such as amyloid-binding positron emission tomography studies, are limited by cost and availability. More...
There is a need for a more practical beta-amyloid (Aβ) biomarker for central nervous system amyloid deposition.

An international team of scientists working with the Japanese National Center for Geriatrics and Gerontology (Obu, Japan) used immunoprecipitation followed by matrix-assisted laser desorption/ionization (MALDI) mass spectrometry to measure levels of the three markers, APP669-711, Aβ42, and Aβ40 in two cohorts, a discovery set consisting of 121 Japanese patients and a validation set consisting of 252 Australian patients. Both sets included a mix of cognitively normal individuals, subjects with mild cognitive impairment, and subjects with clinically diagnosed Alzheimer's disease with dementia. All patients also had Aβ- positron-emission tomography (PET) imaging data, providing an assessment of their brain Aβ burdens. A subset of the Australian patients also had measurements taken of their cerebrospinal fluid Aβ levels.

The tem tested ratios of the three markers to develop a composite blood-based marker corresponding to brain Aβ levels as assessed by PET and cerebrospinal fluid (CSF) measurements. They used ratios as opposed to absolute measurements to account for individual variation in blood Aβ42 levels across individuals. A composite of the three plasma protein ratios corresponded well with both patient Aβ42 CSF levels and brain Aβ42 levels as determined by PET. Using PET measurements as the gold standard, the investigators found their plasma measurements had comparable performance to the CSF measurements, with both showing accuracy of 80.4% and areas under the curve of 83.8% and 87.4% for the blood and CSF measurements, respectively. Using the CSF measurements as the gold standard, the composite plasma markers performed with an accuracy of 80.4% and an AUC of 87.6.

The authors concluded that their results demonstrated the potential clinical utility of plasma biomarkers in predicting brain beta-amyloid burden at an individual level. These plasma biomarkers also have cost–benefit and scalability advantages over current techniques, potentially enabling broader clinical access and efficient population screening. The study was published on January 31, 2018, in the journal Nature.

Related Links:
Japanese National Center for Geriatrics and Gerontology


New
Gold Member
Blood Gas Analyzer
Stat Profile pHOx
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Pan-Cancer Panel
TruSight Oncology 500
New
DNA/RNA Extraction/Purification Kit
Nucleic Acid Extraction or Purification Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.